Peter A. Gottlieb MDOrr Family Endowed Chair in Adult Diabetes; Professor of Pediatrics and Medicine, Barbara Davis Center/University of Colorado School of Medicine, Aurora, Colorado
Dr. Peter Gottlieb is the Orr Family Endowed Chair in Adult Diabetes and a Professor of Pediatrics and Medicine at the Barbara Davis Center at the University of Colorado School of Medicine. His research interests are in autoimmunity of Type 1 Diabetes and other endocrine disorders, the role of T and B lymphocytes in disease pathogenesis and clinical trial design. He is the Chair of the Collaborative Mechanistic Studies Panel for Type 1 Diabetes TrialNet.
Dr. Gottlieb has been involved in many clinical trials to prevent and reverse type 1 diabetes through NIH, industry and investigator-initiated studies. He co-founded ImmunoMolecular Therapeutics, Inc., a spinout from the University of Colorado to develop small molecule inhibitors of antigen presentation. He consults for several biotech and pharma companies and is a consultant to the JDRF T1D Fund.
DisclosuresDr. Gottlieb reports the following:
- Co-founder, CMO and shareholder in IM Therapeutics, Inc.
- Grants/Research – NIH, Helmsley, JDRF, Nova Pharmaceuticals, Intrexon T1D Partners, Novartis, Imcyse, Provention Bio
- Consultant – Provention Bio, Viacyte, Imcyse, JDRF T1D Fund